Modular Medical Announces Formation of Pivot Innovation Council and Appointment of Robert Gabbay, MD, PhD, FACP as Chairman
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) announced the formation of the Pivot Innovation Council, a cross-functional group of clinicians and healthcare experts created to guide clinical and commercial strategy for its Pivot™ tubeless patch pump. Diabetes care leader Robert Gabbay, MD, PhD, FACP has been appointed chairman.
The council will advise on target patient populations, workflow integration, evidence-generation initiatives, and the Pivot product roadmap and go-to-market approach. According to Modular Medical, Dr. Gabbay’s extensive background in diabetes care transformation, population health, and patient-centered care will support efforts to expand clinical evidence, strengthen provider engagement, and improve access to simpler insulin pump therapy.
Positive
- None.
Negative
- None.
News Market Reaction – MODD
In the Jul 23 session, MODD gained 2.70%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.2% during that session. Argus tracked a trough of -23.6% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | Strategic pilot | Positive | -22.7% | Pilot collaboration targeted EHR-based identification of patients who may benefit from Pivot. |
| Jul 15 | Payor research | Positive | -2.8% | Independent research reported positive payor receptivity toward Pivot's design and reimbursement potential. |
| Jul 14 | Patient research | Positive | +9.8% | A 100-person assessment found 97% would consider pump therapy and alternative treatment options. |
| Jul 1 | FDA submission | Positive | +4.0% | Modular Medical submitted Pivot software enhancements to the FDA for review. |
| Jun 30 | Patient launch | Positive | -7.8% | The first patients completed training and began using Pivot in real-world settings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MODD diverged from the positive direction of three of its five recent news events, including the two most recent announcements.
Key Terms
tubeless patch pump medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Council to Provide Strategic Clinical Guidance on Commercialization, Patient Identification, Workflow Integration, and Evidence Generation
SAN DIEGO, CA / ACCESS Newswire / July 23, 2026 / Modular Medical, Inc, ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company's clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.
"The formation of the Pivot Innovation Council represents an important milestone for us, as we deepen our engagement with clinicians and healthcare stakeholders," said Jeb Besser, CEO. "By bringing together leading experts across disciplines, we are creating a forum that we believe will help ensure our solutions address real-world clinical needs and deliver meaningful value to providers, health systems, and patients."
"We are honored to welcome Dr. Gabbay as chair of the Pivot Innovation Council," continued Mr. Besser. "His unique combination of clinical expertise, healthcare transformation leadership, and deep experience advancing patient-centered care models will be invaluable as we continue to build clinical evidence, strengthen provider engagement, and expand our impact on patient outcomes."
Dr. Gabbay is internationally recognized for his work transforming diabetes care through innovative delivery models, population health strategies, and quality improvement initiatives. Over the course of his career, Dr. Gabbay has held numerous leadership roles dedicated to advancing diabetes care nationally and globally, including executive leadership positions with the American Diabetes Association and Harvard's Joslin Diabetes Center. His work has helped define and implement patient-centered care models across hundreds of clinical practices and has influenced healthcare delivery strategies worldwide.
Dr. Gabbay has led efforts to improve patient outcomes through care management programs, digital health solutions, clinical decision support tools, patient engagement strategies, and large-scale diabetes registries. His research and care transformation initiatives have been supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and the Center for Medicare & Medicaid Innovation. A respected clinician, researcher, and healthcare leader, Dr. Gabbay earned his bachelor's degree from McGill University, a PhD in Biochemistry from the University of Wisconsin, and his medical degree from the State University of New York Downstate Medical Center. He completed his residency in Internal Medicine at New York Hospital-Cornell Medical Center and a fellowship in Endocrinology, Diabetes, and Metabolism through the joint Joslin Diabetes Center, Beth Israel Deaconess Medical Center, and Brigham and Women's Hospital training program. He has also served as a visiting scientist at MIT and as a Professor of Medicine at Penn State College of Medicine.
Under Dr. Gabbay's leadership, Modular Medical will assemble a multidisciplinary Pivot Innovation Council tasked with advancing key clinical, evidence-generation, and care-delivery initiatives. The Council will focus on addressing the needs of patients who may benefit from a simpler, more accessible insulin pump experience, helping shape the future of diabetes management through practical innovation, clinical insight, and patient-centered care.
About Modular Medical, Inc.
Modular Medical, Inc. (NASDAQ:MODD) is a commercial-stage medical device company focused on the development of innovative insulin delivery technologies designed to simplify diabetes management and increase access to insulin pump therapy. The Company's Pivot™ tubeless patch pump has been developed to provide a user-friendly, flexible, and accessible approach to insulin delivery for people requiring intensive insulin therapy.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's plans for the Pivot Innovation Council, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
Company Contact:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
IR@modular-medical.com
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KCSA.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire